Enhanced Survival in Acute Promyelocytic leukemia: A New Era of Therapeutic and Supportive Interventions

Main Article Content

Muhammed Usman Shaikh Nabiha Saeed

Abstract

Acute promyelocytic leukemia is a distinct subtype of acute myeloid leukemia characterized by a reciprocal chromosomal translocation involving the retinoic acid receptor-alpha (RARα) gene and exhibiting characteristic morphological and clinical features, with significant early mortality. With the advent of arsenic trioxide and all-trans retinoic acid the prognosis of acute promyelocytic leukemia has improved. However, early induction mortality remains a significant challenge, with hemorrhagic complications and differentiation syndrome being major contributors to morbidity and mortality. Management of acute promyelocytic leukemia has undergone significant advancements, resulting in improved mortality rates and enhanced five-year survival rates exceeding 80%. Despite these gains, early induction mortality and differentiation syndrome remain pressing challenges. This review underscores the importance of proactive interventions, including early administration of blood products and corticosteroids, and highlights the need for continued research into differentiation syndrome prevention strategies. Our review also underscores the need for continued research to improve outcomes in patients with APL, particularly in low- and middle-income countries where access to healthcare and treatment options are limited.

Article Details

How to Cite
SHAIKH, Muhammed Usman; SAEED, Nabiha. Enhanced Survival in Acute Promyelocytic leukemia: A New Era of Therapeutic and Supportive Interventions. Medical Research Archives, [S.l.], v. 13, n. 1, jan. 2025. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6119>. Date accessed: 10 feb. 2025. doi: https://doi.org/10.18103/mra.v13i1.6119.
Section
Research Articles

References

1. Stanley M, McKenna RW, Ellinger G, Brunning RD. Classification of 358 cases of acute myeloid leukemia by FAB criteria: analysis of clinical and morphologic features. Chronic and acute leukemias in adults: Springer; 1985. p. 147-74.

2. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, The Journal of the American Society of Hematology. 2009;113 (9):1875-91.

3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Annals of internal medicine. 1985;103(4): 620-5.

4. McKenna R, Kyle R, Kuehl W, Grogan T, Harris N, Coupland R. WHO classification of tumours of haematopoietic and lymphoid tissues. Plasma cell neoplasms Lyon: IARC. 2008:200-13.

5. Candoni A, Damiani D, Michelutti A, Masolini P, Michieli M, Michelutti T, et al. Clinical characteristics, prognostic factors and multidrug‐resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. European journal of haematology. 2003;71(1):1-8.

6. Stone RM, Mayer R. The unique aspects of acute promyelocytic leukemia. Journal of Clinical Oncology. 1990;8(11):1913-21.

7. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood, The Journal of the American Society of Hematology. 2002;99(3):759-67.

8. Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon M-F. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 1973;41(4):489-96.

9. Zhang L, Zhu X. Epidemiology, diagnosis and treatment of acute promyelocytic leukemia in children: the experience in China. Mediterranean journal of hematology and infectious diseases. 2012;4(1).

10. Meng-Er H, Yu-Chen Y, Shu-Rong C, Jin-Ren C, Jia-Xiang L, Lin Z, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-72.

11. Zx S. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101:5328-35.

12. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, The Journal of the American Society of Hematology. 2017;129(10):1275-83.

13. Thomas X. Acute promyelocytic leukemia: a history over 60 years—from the most malignant to the most curable form of acute leukemia. Oncology and therapy. 2019;7(1):33-65.

14. Pandolfi PP, Chen Z. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. Cancer cell. 2017;32(5):552-60.

15. Kwaan HC, Weiss I, Tallman MS, editors. The role of abnormal hemostasis and fibrinolysis in morbidity and mortality of acute promyelocytic leukemia. Seminars in thrombosis and hemostasis; 2019: Thieme Medical Publishers.

16. Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, The Journal of the American Society of Hematology. 2019;133(15):1630-43.

17. Woods AC, Norsworthy KJ. Differentiation Syndrome in Acute Leukemia: APL and Beyond. Cancers. 2023;15(19):4767.

18. Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. British journal of haematology. 2019;187(2):157-62.

19. Luesink M, Pennings JL, Wissink WM, Linssen PC, Muus P, Pfundt R, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood, The Journal of the American Society of Hematology. 2009;114(27):55 12-21.

20. Taraboletti G, Borsotti P, Chirivi RG, Vergani V, Falanga A, Barbui T, et al. Effect of all trans‐retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. International journal of cancer. 1997;70(1):72-7.

21. Montesinos P, Sanz MA. The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. Mediterranean journal of hematology and infectious diseases. 2011;3(1).

22. Yoon J-H, Kim H-J, Min GJ, Park S-S, Jeon Y-W, Lee S-E, et al. Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia. Scientific reports. 2019;9(1):11935.

23. Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood, The Journal of the American Society of Hematology. 2014; 123(18):2777-82.

24. De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood, The Journal of the American Society of Hematology. 1998;92(8):2712-8.

25. Sanz MA, Montesinos P, Vellenga E, Rayón C, De La Serna J, Parody R, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood, The Journal of the American Society of Hematology. 2008;112(8):31 30-4.

26. Wu Q, Wu D-P, Chen S, Yang X, Zhang J, Xue M, et al. Improved Prevention and Treatment Strategy of Differentiation Syndrome Contribute to Reduce Early Death of Patients with Acute Promyelocytic Leukemia. Blood. 2023;142:1528.

27. LaBella D, Regan S, Konig H, Egan DN, Bailey NA, Mawad R, et al. The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome. Frontiers in Oncology. 2022;12:911745.

28. Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood cancer journal. 2021;11(2):41.

29. Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F. Acute promyelocytic leukemia: A population‐based study on incidence and survival in the United States, 1975‐2008. Cancer. 2012;118 (23):5811-8.

30. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):11 28-34.

31. Paulson K, Serebrin A, Lambert P, Bergeron J, Everett J, Kew A, et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan‐C anadian epidemiological study. British journal of haematology. 2014;166(5):660-6.

32. Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, The Journal of the American Society of Hematology. 2011;118(5):12 48-54.

33. McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97(1):133.

34. Jillella AP, Kolhe RB, Natrajan K, Kota V. A successful model to decrease early deaths in acute promyelocytic leukemia (APL) through the use of a simplified algorithm and expert support. American Society of Clinical Oncology; 2014.

35. Yedla RP, Bala SC, Pydi VR, Kuruva SP, Chennamaneni R, Konatam ML, et al. Outcomes in adult acute promyelocytic leukemia: a decade experience. Clinical Lymphoma Myeloma and Leukemia. 2020;20(4):e158-e64.

36. Vaid T, Aggarwal M, Kumar P, Dhawan R, Dass J, Viswanathan G, et al. Clinical Profile, Complications and Outcomes of Patients with Acute Promyelocytic Leukemia: Indian Perspective. Blood. 2021;138:4385.

37. Bajpai J, Sharma A, Kumar L, Dabkara D, Raina V, Kochupillai V, et al. Acute promyelocytic leukemia: an experience from a tertiary care centre in north India. Indian journal of Cancer. 2011;48(3):316-22.

38. Sindhusha K, C Saldanha S, Abraham Jacob L, Suresh Babu M, Lokesh K, Rudresha A, et al. Clinico-Pathological Significance and Prognostic Impact of Various PML RARA Transcripts on Outcomes in Acute Promyelocytic Myeloid Leukemia (APML) Treated with Single Agent Arsenic Trioxide (ATO)-Insights from a Tertiary Cancer Center in South India. Indian Journal of Hematology and Blood Transfusion. 2024:1-6.

39. Naz S, Ghafoor T, Manzoor R, Hira B, Ahmed S, Arshed A. Outcomes of Acute Promyelocytic Leukaemia in Paediatric Patients: Insights from a Low-Middle-Income Country. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP. 2024; 34(8):974-80.

40. Raza S, Ullah K, Ahmed P, Khan B. Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia. J Coll Physicians Surg Pak. 2008;18(9):546-50.

41. Shaikh MU, Ali N, Karim F, Raheem A, Sarwar S. Improved outcome in early induction deaths in patients with acute promyelocytic leukemia after therapeutic and supportive interventions: a follow up study of seven-years’ experience at a tertiary care center. American Journal of Blood Research. 2020;10(4):82.